A pilot study using nabilone for symptomatic treatment in Huntington's disease
Identifieur interne : 002E41 ( Istex/Curation ); précédent : 002E40; suivant : 002E42A pilot study using nabilone for symptomatic treatment in Huntington's disease
Auteurs : Adrienne Curtis [Royaume-Uni] ; Ian Mitchell [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Hugh Rickards [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-11-15.
English descriptors
Abstract
Pilot study of nabilone in Huntington's disease (HD). Double‐blind, placebo‐controlled, cross‐over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: −1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: −3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: −0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22809
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002E41
Links to Exploration step
ISTEX:61E6C434C0A8437E3F399E156F16677D97B934DFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot study using nabilone for symptomatic treatment in Huntington's disease</title><author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name><affiliation wicri:level="1"><mods:affiliation>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham</wicri:regionArea></affiliation></author><author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name><affiliation wicri:level="1"><mods:affiliation>University of Birmingham School of Psychology, Edgbaston, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Birmingham School of Psychology, Edgbaston, Birmingham</wicri:regionArea></affiliation></author><author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name><affiliation wicri:level="1"><mods:affiliation>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham</wicri:regionArea></affiliation></author><author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name><affiliation wicri:level="1"><mods:affiliation>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham</wicri:regionArea></affiliation></author><author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name><affiliation wicri:level="1"><mods:affiliation>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:61E6C434C0A8437E3F399E156F16677D97B934DF</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22809</idno><idno type="url">https://api.istex.fr/document/61E6C434C0A8437E3F399E156F16677D97B934DF/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002E41</idno><idno type="wicri:Area/Istex/Curation">002E41</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A pilot study using nabilone for symptomatic treatment in Huntington's disease</title><author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name><affiliation wicri:level="1"><mods:affiliation>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham</wicri:regionArea></affiliation></author><author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name><affiliation wicri:level="1"><mods:affiliation>University of Birmingham School of Psychology, Edgbaston, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Birmingham School of Psychology, Edgbaston, Birmingham</wicri:regionArea></affiliation></author><author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name><affiliation wicri:level="1"><mods:affiliation>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham</wicri:regionArea></affiliation></author><author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name><affiliation wicri:level="1"><mods:affiliation>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham</wicri:regionArea></affiliation></author><author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name><affiliation wicri:level="1"><mods:affiliation>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-11-15">2009-11-15</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="2254">2254</biblScope><biblScope unit="page" to="2259">2259</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">61E6C434C0A8437E3F399E156F16677D97B934DF</idno><idno type="DOI">10.1002/mds.22809</idno><idno type="ArticleID">MDS22809</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington's disease</term><term>cannabinoids</term><term>chorea</term><term>nabilone</term><term>psychiatric symptoms</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pilot study of nabilone in Huntington's disease (HD). Double‐blind, placebo‐controlled, cross‐over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: −1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: −3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: −0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. © 2009 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 002E41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:61E6C434C0A8437E3F399E156F16677D97B934DF
|texte= A pilot study using nabilone for symptomatic treatment in Huntington's disease
}}
| This area was generated with Dilib version V0.6.23. |  |